The only HIV vaccine in a late-stage trial has failed, researchers say.
, for a global rollout. Instead, he retired from his post at the end of last month with this dream unfulfilled., which is headquartered in the Fred Hutchinson Research Center in Seattle, and the U.S. Army Medical Research and Development Command., of a separate clinical trial, called Imbokodo, which tested a similar vaccine among women in Africa. Between the two trials, NIAID spent $56 million, according to an agency spokesperson.
Participants in Mosaico, who were between ages 18 and 60, received four injections over 12 months, either of the vaccine or a placebo. The monitoring board found no significant difference in the HIV acquisition rate between the two study groups. Fauci said that a critical limitation of the Mosaico vaccine was that it elicited what are known as non-neutralizing — as opposed to neutralizing — antibodies against HIV.
“It is becoming clear,” he said, “that vaccines that do not induce neutralizing antibodies are not effective against HIV.”rely upon the cutting-edge mRNA vaccine technology behindThe critical problem that has bedeviled HIV vaccine research for decades, Fauci noted, is a crucial weakness that the virus already successfully exploits: The natural immune response to infection is not sufficient to thwart the virus.
“So vaccines would actually have to do better than natural infection to be effective,” he said. “That would be a very high bar.”In 1984, following the discovery of HIV as the cause of AIDS the previous year, President Ronald Reagan’s health secretary, Margaret Heckler,In the decades since, there have been nine late-stage clinical trials of HIV vaccines, including Mosaico and Imbokodo, plus one,
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
J&J to discontinue HIV vaccine trialJohnson & Johnson said on Wednesday that it was pulling the plug on a late-stage global trial of an HIV vaccine after the shot was found ineffective at preventing infections.
Baca lebih lajut »
J&J’s HIV vaccine fails Phase 3 clinical trialJohnson & Johnson’s experimental HIV vaccine is safe but not effective, and the late-stage study will be discontinued as a result of that finding, federal...
Baca lebih lajut »
Johnson & Johnson ends trial for HIV vaccine after data show it is ineffectiveJohnson & Johnson said Wednesday that it has ended a late-stage trial for its experimental HIV vaccine after data showed the shot was ineffective at preventing infections.
Baca lebih lajut »
First Mover Americas: Three Arrows' Founders Take Slingshot From Crypto CommunityThe number of $BTC owned by wallets of OTC desks has risen since Jan. 11. It's a sign that institutional investors such as hedge funds that typically use the desks for large transactions are buying bitcoin.
Baca lebih lajut »
First Mover Americas: Crypto Winter Chills at Digital Currency Group, CoinbaseIn the wake of the collapse of FTX_Official, more $BTC is being held in self-custody in offline thumb drives instead of in central exchanges.
Baca lebih lajut »